FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891936204> ?p ?o ?g. }

• W2891936204 abstract "10543 Background: CNS malignancies are the most common solid tumors among children. Novel therapies are needed to help improve the survival outcomes in children with recurrent disease. Pomalidomide is an immunomodulatory agent thought to also function through a combination of anti-angiogenic, anti-inflammatory and cytotoixic activity making it a good candidate to explore in pediatric CNS tumors. Methods: A Phase I trial of pomalidomide was conducted among children ≥ 3 to < 21 years old with recurrent, progressive/refractory CNS tumors using the “rolling 6” dose escalation design. The primary objective was to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) when given orally once daily for 21 consecutive days of a 28-day course. Once the MTD was established, 12 additional patients were enrolled on expansion cohorts based on age and steroid use. Results: 29 children were enrolled and 25 were evaluable for dose limiting toxicity (DLT) evaluation. The MTD was 2.6 mg/m 2 (Dose level 2). DLTs observed at dose level 3 (3.4 mg/m 2 ) included diarrhea (n = 1), thrombocytopenia (n = 1) and lung infection (n = 1), all grade 3. The most common toxicities were grade 1 lymphopenia (55%), leukopenia (62%) and thrombocytopenia (38%). There were no obvious differences in tolerability based on age or steroid use. Pharmacokinetics were similar to those observed in adults and increased in a dose-dependent manner. At the RP2D of 2.6 mg/m 2 , the C max was 97.4 ng/mL and the t½ was 4.1 hours. The median number of treatment cycles was 1.6 (0.2-12.3). Two patients, one with an oligodendroglioma and one with anaplastic pleomorphic xanthoastrocytoma, had long term stable disease for 9 and 18+ cycles. No objective responses were observed. Twelve month progression-free and overall-survivals were 5.2+/-3.6% and 12.8+/-8.5%, respectively. Immunologic correlate analyses are ongoing. Conclusions: The RP2D of pomalidomide is 2.6 mg/m 2 in children with recurrent brain tumors. Further prospective evaluation of this agent alone or in combination will be necessary to better understand its efficacy in specific pediatric CNS tumor populations. Clinical trial information: NCT02415153." @default.
• W2891936204 created "2018-09-27" @default.
• W2891936204 creator A5002306055 @default.
• W2891936204 creator A5002952095 @default.
• W2891936204 creator A5016039890 @default.
• W2891936204 creator A5034912564 @default.
• W2891936204 creator A5039750788 @default.
• W2891936204 creator A5065578155 @default.
• W2891936204 creator A5067969166 @default.
• W2891936204 creator A5068118481 @default.
• W2891936204 creator A5071013421 @default.
• W2891936204 creator A5073101952 @default.
• W2891936204 creator A5087959258 @default.
• W2891936204 date "2017-05-20" @default.
• W2891936204 modified "2023-09-28" @default.
• W2891936204 title "A phase I trial of pomalidomide for children with recurrent, progressive/refractory central nervous system (CNS) tumors: A Pediatric Brain Tumor Consortium (PBTC) study." @default.
• W2891936204 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10543" @default.
• W2891936204 hasPublicationYear "2017" @default.
• W2891936204 type Work @default.
• W2891936204 sameAs 2891936204 @default.
• W2891936204 citedByCount "1" @default.
• W2891936204 countsByYear W28919362042021 @default.
• W2891936204 crossrefType "journal-article" @default.
• W2891936204 hasAuthorship W2891936204A5002306055 @default.
• W2891936204 hasAuthorship W2891936204A5002952095 @default.
• W2891936204 hasAuthorship W2891936204A5016039890 @default.
• W2891936204 hasAuthorship W2891936204A5034912564 @default.
• W2891936204 hasAuthorship W2891936204A5039750788 @default.
• W2891936204 hasAuthorship W2891936204A5065578155 @default.
• W2891936204 hasAuthorship W2891936204A5067969166 @default.
• W2891936204 hasAuthorship W2891936204A5068118481 @default.
• W2891936204 hasAuthorship W2891936204A5071013421 @default.
• W2891936204 hasAuthorship W2891936204A5073101952 @default.
• W2891936204 hasAuthorship W2891936204A5087959258 @default.
• W2891936204 hasConcept C121332964 @default.
• W2891936204 hasConcept C126322002 @default.
• W2891936204 hasConcept C142424586 @default.
• W2891936204 hasConcept C143998085 @default.
• W2891936204 hasConcept C2776063141 @default.
• W2891936204 hasConcept C2778524551 @default.
• W2891936204 hasConcept C2780401358 @default.
• W2891936204 hasConcept C529278444 @default.
• W2891936204 hasConcept C71924100 @default.
• W2891936204 hasConcept C87355193 @default.
• W2891936204 hasConceptScore W2891936204C121332964 @default.
• W2891936204 hasConceptScore W2891936204C126322002 @default.
• W2891936204 hasConceptScore W2891936204C142424586 @default.
• W2891936204 hasConceptScore W2891936204C143998085 @default.
• W2891936204 hasConceptScore W2891936204C2776063141 @default.
• W2891936204 hasConceptScore W2891936204C2778524551 @default.
• W2891936204 hasConceptScore W2891936204C2780401358 @default.
• W2891936204 hasConceptScore W2891936204C529278444 @default.
• W2891936204 hasConceptScore W2891936204C71924100 @default.
• W2891936204 hasConceptScore W2891936204C87355193 @default.
• W2891936204 hasLocation W28919362041 @default.
• W2891936204 hasOpenAccess W2891936204 @default.
• W2891936204 hasPrimaryLocation W28919362041 @default.
• W2891936204 hasRelatedWork W126820095 @default.
• W2891936204 hasRelatedWork W168273083 @default.
• W2891936204 hasRelatedWork W186467362 @default.
• W2891936204 hasRelatedWork W1965211560 @default.
• W2891936204 hasRelatedWork W1970792057 @default.
• W2891936204 hasRelatedWork W2004909433 @default.
• W2891936204 hasRelatedWork W2023281320 @default.
• W2891936204 hasRelatedWork W2469458301 @default.
• W2891936204 hasRelatedWork W2549116575 @default.
• W2891936204 hasRelatedWork W2626653746 @default.
• W2891936204 hasRelatedWork W2665970608 @default.
• W2891936204 hasRelatedWork W2808747513 @default.
• W2891936204 hasRelatedWork W2898148645 @default.
• W2891936204 hasRelatedWork W2899977175 @default.
• W2891936204 hasRelatedWork W2940862633 @default.
• W2891936204 hasRelatedWork W2947741083 @default.
• W2891936204 hasRelatedWork W3030291615 @default.
• W2891936204 hasRelatedWork W3169001700 @default.
• W2891936204 hasRelatedWork W3198287841 @default.
• W2891936204 hasRelatedWork W606542372 @default.
• W2891936204 isParatext "false" @default.
• W2891936204 isRetracted "false" @default.
• W2891936204 magId "2891936204" @default.
• W2891936204 workType "article" @default.